Managing the patient with chronic viral hepatitis receiving chemotherapy

When Cancer Crosses Disciplines: A Physician's Handbook

Volumn , Issue , 2009, Pages 813-831

  Pattullo, Venessa ^a   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chemotherapy; Hepatitis B; Lamivudine; Prophylaxis; Reactivation

Indexed keywords

EID: 84929006269     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781848163652_0032     Document Type: Chapter

References (46)

1. J. Benson and W. Donohue, Hepatitis in refugees who settle in Australia, Aust. Fam. Physician 36: 719-727 (2007).
2. R. Mohamed, P. Desmond, D. J. Suh, D. Amarapurkar, E. Gane, Y. Guangbi, J. L. Hou, W. Jafri, C. L. Lai, C. H. Lee, S. D. Lee, S. G. Lim, R. Guan, P. H. Phiet, T. Piratvisuth, J. Sollano and J. C. Wu, Practical difficulties in the management of hepatitis B in the Asia-Pacific region, J. Gastroenterol. Hepatol. 19: 958-969 (2004).
3. H. M. Tawk, K. Vickery, L. Bisset, S. K. Lo, W. Selby and Y. E. Cossart, The current pattern of hepatitis B virus infection in Australia, J. Viral Hepat. 13: 206-215 (2006).
4. P. Pavli, G. J. Bayliss, O. F. Dent and M. L. Lunzer, The prevalence of serological markers for hepatitis B virus infection in Australian Naval personnel, Med. J. Aust. 151: 71, 74-75 (1989).
5. B. G. O’Sullivan, H. F. Gidding, M. Law, J. M. Kaldor, G. L. Gilbert and G. J. Dore, Estimates of chronic hepatitis B virus infection in Australia, 2000, Aust. N. Z. J. Public Health 28: 212-216 (2004).
6. M. Esteve, C. Saro, F. Gonzalez-Huix, F. Suarez, M. Forne and J. M. Viver, Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: Need for primary prophylaxis, Gut 53: 1363-1365 (2004).
7. L. H. Calabrese, N. N. Zein and D. Vassilopoulos, Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: Assessment and preventive strategies, Ann. Rheum. Dis. 65: 983-989 (2006).
8. V. G. Bain, Hepatitis B in transplantation, Transpl. Infect. Dis. 2: 153-165 (2000).
9. A. Berger, W. Preiser, H. G. Kache, M. Sturmer and H. W. Doerr, HBV reactivation after kidney transplantation, J. Clin. Virol. 32: 162-165 (2005).
10. G. Dusheiko, E. Song, S. Bowyer, M. Whitcutt, G. Maier, A. Meyers and M. C. Kew, Natural history of hepatitis B virus infection in renal transplant recipients - Afifteen-year follow-up, Hepatology 3: 330-336 (1983).
11. E. Gane and H. Pilmore, Management of chronic viral hepatitis before and after renal transplantation, Transplantation 74: 427-437 (2002).
12. J. Kletzmayr and B. Watschinger, Chronic hepatitis B virus infection in renal transplant recipients, Semin. Nephrol. 22: 375-389 (2002).
13. M. G. Chheda, J. Drappatz, N. J. Greenberger, S. Kesari, S. E. Weiss, D. C. Gigas, L. M. Doherty and P. Y. Wen, Hepatitis B reactivation during glioblastoma treatment with temozolomide: A cautionary note, Neurology 68: 955-956 (2007).
14. B. Coiffier, Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: Role of lamivudine prophylaxis, Cancer Invest. 24: 548-552 (2006).
15. M. S. Dai, P. F. Wu, R. Y. Shyu, J. J. Lu and T. Y. Chao, Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration, Liver Int. 24: 540-546 (2004).
16. H. Higashiyama, T. Harabayashi, N. Shinohara, M. Chuma, S. Hige and K. Nonomura, Reactivation of hepatitis in a bladder cancer patient receiving chemotherapy, Int. Urol. Nephrol. 39: 461-463 (2007).
17. W. Yeo, E. P. Hui, A. T. Chan, W. M. Ho, K. C. Lam, P. K. Chan, T. S. Mok, J. J. Lee, F. K. Mo and P. J. Johnson, Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine, Am. J. Clin. Oncol. 28: 379-384 (2005).
18. W. Yeo and P. J. Johnson, Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy, Hepatology 43: 209-220 (2006).
19. W. Yeo, K. C. Lam, B. Zee, P. S. Chan, F. K. Mo, W. M. Ho, W. L. Wong, T. W. Leung, A. T. Chan, B. Ma, T. S. Mok and P. J. Johnson, Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy, Ann. Oncol. 15: 1661-1666 (2004).
20. D. M. Nathan, P. W. Angus and P. R. Gibson, Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: Guidelines for clinical approach, J. Gastroenterol. Hepatol. 21: 1366-1371 (2006).
21. W. Yeo, P. K. Chan, S. Zhong, W. M. Ho, J. L. Steinberg, J. S. Tam, P. Hui, N. W. Leung, B. Zee and P. J. Johnson, Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors, J. Med. Virol. 62: 299-307 (2000).
22. H. C. Thomas, Best practice in the treatment of chronic hepatitis B: A summary of the European Viral Hepatitis Educational Initiative (EVHEI), J. Hepatol. 47: 588-597 (2007).
23. Y. F. Liaw, I. S. Sheen, T. J. Chen, C. M. Chu and C. C. Pao, Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study, Hepatology 13: 627-631 (1991).
24. C. Brechot, F. Degos, C. Lugassy, V. Thiers, S. Zafrani, D. Franco, H. Bismuth, C. Trepo, J. P. Benhamou, J. Wands et al., Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen, N. Engl. J. Med. 312: 270-276 (1985).
25. I. Chemin, D. Jeantet, A. Kay and C. Trepo, Role of silent hepatitis B virus in chronic hepatitis B surface antigen(−) liver disease, Antiviral Res. 52: 117-123 (2001).
26. J. R. Wands, C. M. Chura, F. J. Roll and W. C. Maddrey, Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders, Gastroenterology 68: 105-112 (1975).
27. N. Schnepf, P. Sellier, M. Bendenoun, J. M. Zini, M. J. Sanson-le Pors and M. C. Mazeron, Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy, J. Clin. Virol. 39: 48-50 (2007).
28. H. Marusawa, S. Imoto, Y. Ueda and T. Chiba, Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen, J. Gastroenterol. 36: 633-636 (2001).
29. J. K. Law, J. K. Ho, P. J. Hoskins, S. R. Erb, U. P. Steinbrecher and E. M. Yoshida, Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations, Leuk. Lymphoma 46: 1085-1089 (2005).
30. C. Hsu, C. A. Hsiung, I. J. Su, W. S. Hwang, M. C. Wang, S. F. Lin, T. H. Lin, H. H. Hsiao, J. H. Young, M. C. Chang, Y. M. Liao, C. C. Li, H. B. Wu, H. F. Tien, T. Y. Chao, T. W. Liu, A. L. Cheng and P. J. Chen, A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: A randomized trial, Hepatology 47: 844-853 (2008).
31. A. Marzano, E. Angelucci, P. Andreone, M. Brunetto, R. Bruno, P. Burra, P. Caraceni, B. Daniele, V. Di Marco, F. Fabrizi, S. Fagiuoli, P. Grossi, P. Lampertico, R. Meliconi, A. Mangia, M. Puoti, G. Raimondo and A. Smedile, Prophylaxis and treatment of hepatitis B in immunocompromised patients, Dig. Liver Dis. 39: 397-408 (2007).
32. W. Yeo, W. M. Ho, P. Hui, P. K. Chan, K. C. Lam, J. J. Lee and P. J. Johnson, Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients, Breast Cancer Res. Treat. 88: 209-215 (2004).
33. Y. H. Li, Y. F. He, W. Q. Jiang, F. H. Wang, X. B. Lin, L. Zhang, Z. J. Xia, X. F. Sun, H. Q. Huang, T. Y. Lin, Y. J. He and Z. Z. Guan, Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma, Cancer 106: 1320-1325 (2006).
34. R. Loomba, A. Rowley, R. Wesley, T. J. Liang, J. H. Hoofnagle, F. Pucino and G. Csako, Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy, Ann. Intern. Med. 148: 519-528 (2008).
35. L. A. Martyak, E. Taqavi and S. Saab, Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: A meta-analysis, Liver Int. 28: 28-38 (2008).
36. S. Saab, M. H. Dong, T. A. Joseph and M. J. Tong, Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model, Hepatology 46: 1049-1056 (2007).
37. G. Lalazar, D. Rund and D. Shouval, Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies, Br. J. Haematol. 136: 699-712 (2007).
38. A. S. Lok and C. L. Lai, Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology, J. Hepatol. 10: 29-34 (1990).
39. A. S. Lok, R. H. Liang, E. K. Chiu, K. L. Wong, T. K. Chan and D. Todd, Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study, Gastroenterology 100: 182-188 (1991).
40. M. S. Jazayeri, A. A. Basuni, G. Cooksley, S. Locarnini and W. F. Carman, Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region, J. Hepatol. 41: 139-146 (2004).
41. G. K. Lau, H. H. Yiu, D. Y. Fong, H. C. Cheng, W. Y. Au, L. S. Lai, M. Cheung, H. Y. Zhang, A. Lie, R. Ngan and R. Liang, Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy, Gastroenterology 125: 1742-1749 (2003).
42. A. S. Lok and B. J. McMahon, Chronic hepatitis B, Hepatology 45: 507-539 (2007).
43. D. Francisci, F. Aversa, V. Coricelli, A. Carotti, B. Canovari, F. Falcinelli, B. Belfiori, T. Aloisi, F. Baldelli, M. F. Martelli and G. Stagni, Prevalence, incidence and clinical outcome of hepatitis B virus and hepatitis C virus hepatitis in patients undergoing allogeneic hematopoietic stem cell transplantation between 2001 and 2004, Haematologica 91: 980-982 (2006).
44. P. Faggioli, M. De Paschale, A. Tocci, M. Luoni, S. Fava, A. De Paoli, A. Tosi and E. Cassi, Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma, Haematologica 82: 38-42 (1997).
45. A. Gruber, L. G. Lundberg and M. Bjorkholm, Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy, J. Intern. Med. 234: 223-225 (1993).
46. M. E. Melisko, R. Fox and A. Venook, Reactivation of hepatitis C virus after chemotherapy for colon cancer, Clin. Oncol. (R. Coll. Radiol.) 16: 204-205 (2004).